NO942912L - Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 - Google Patents

Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Info

Publication number
NO942912L
NO942912L NO942912A NO942912A NO942912L NO 942912 L NO942912 L NO 942912L NO 942912 A NO942912 A NO 942912A NO 942912 A NO942912 A NO 942912A NO 942912 L NO942912 L NO 942912L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
monoclonal antibody
human interleukin
cloning
expression
Prior art date
Application number
NO942912A
Other languages
English (en)
Norwegian (no)
Other versions
NO942912D0 (cs
Inventor
Chuan-Chu Chou
Nicholas J Murgolo
John S Abrams
Chung-Her Jehn
Mary E Petro
Jon E Silver
Stephen Tindall
William T Windsor
Paul J Zavodny
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO942912D0 publication Critical patent/NO942912D0/no
Publication of NO942912L publication Critical patent/NO942912L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO942912A 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 NO942912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06
PCT/US1993/000759 WO1993016184A1 (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (2)

Publication Number Publication Date
NO942912D0 NO942912D0 (cs) 1994-08-05
NO942912L true NO942912L (no) 1994-10-06

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942912A NO942912L (no) 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (cs)
EP (1) EP0625201A1 (cs)
JP (2) JPH07505767A (cs)
KR (2) KR0150060B1 (cs)
CN (1) CN1077991A (cs)
AR (1) AR248044A1 (cs)
AU (1) AU683836B2 (cs)
CA (1) CA2129445A1 (cs)
CZ (1) CZ291039B6 (cs)
FI (1) FI943635A7 (cs)
HU (1) HUT67943A (cs)
IL (1) IL104620A (cs)
NO (1) NO942912L (cs)
NZ (1) NZ249633A (cs)
PL (1) PL176393B1 (cs)
RU (1) RU94045919A (cs)
SG (1) SG49597A1 (cs)
SK (1) SK280610B6 (cs)
TN (1) TNSN93012A1 (cs)
WO (1) WO1993016184A1 (cs)
ZA (1) ZA93779B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280610B6 (sk) 1992-02-06 2000-05-16 Schering Corporation Monoklonálna a humanizovaná monoklonálna protilátk
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DE69535319T2 (de) * 1994-12-23 2007-07-19 Smithkline Beecham Corp. Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1527100B1 (en) 2002-03-29 2009-07-01 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP3241915B1 (en) * 2002-10-16 2021-06-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ATE541585T1 (de) 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ES2492943T3 (es) 2007-04-30 2014-09-10 Glaxosmithkline Llc Procedimientos de administración de anticuerpos anti-IL5
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
JP2012506243A (ja) * 2008-10-23 2012-03-15 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンをコードする核酸の決定
EA201390923A1 (ru) * 2010-12-22 2013-12-30 Сефалон Острэйлиа Пти Лтд. Модифицированное антитело с улучшенным полупериодом существования
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
KR102495432B1 (ko) 2014-09-08 2023-02-03 세파론 엘엘씨 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
PH12018500379B1 (en) 2015-08-24 2022-11-23 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
US11365247B2 (en) * 2017-09-29 2022-06-21 Jiangsu Hengrui Medicine Co., Ltd. IL-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
EP0367596B1 (en) * 1988-11-03 1993-12-22 Schering Corporation Antagonist to interleukin-5 for preventing or reducing eosinophilia
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
SK280610B6 (sk) 1992-02-06 2000-05-16 Schering Corporation Monoklonálna a humanizovaná monoklonálna protilátk

Also Published As

Publication number Publication date
CZ191094A3 (en) 1994-12-15
WO1993016184A1 (en) 1993-08-19
ZA93779B (en) 1993-08-05
HUT67943A (en) 1995-05-29
SG49597A1 (en) 1998-06-15
AU683836B2 (en) 1997-11-27
RU94045919A (ru) 1996-11-10
KR950700413A (ko) 1995-01-16
JPH07505767A (ja) 1995-06-29
KR0150060B1 (ko) 1998-08-17
SK91894A3 (en) 1995-02-08
FI943635L (fi) 1994-08-05
JP2000210097A (ja) 2000-08-02
SK280610B6 (sk) 2000-05-16
IL104620A (en) 2000-02-29
FI943635A0 (fi) 1994-08-05
TNSN93012A1 (fr) 1994-03-17
AU3656093A (en) 1993-09-03
IL104620A0 (en) 1993-06-10
PL176393B1 (pl) 1999-05-31
US6451982B1 (en) 2002-09-17
EP0625201A1 (en) 1994-11-23
CN1077991A (zh) 1993-11-03
HU9402293D0 (en) 1994-10-28
CA2129445A1 (en) 1993-08-07
FI943635A7 (fi) 1994-08-05
NO942912D0 (cs) 1994-08-05
NZ249633A (en) 1995-12-21
AR248044A1 (es) 1995-05-31
CZ291039B6 (cs) 2002-12-11

Similar Documents

Publication Publication Date Title
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
ATE208820T1 (de) Humanisierte antikoerper
GB2286399A (en) Recombinant humanized anti-cytomegalovirus antibodies
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PT100195A (pt) Anticorpos monoclonais quimericos e humanos que se ligam a epitopos de receptores de factor de crescimento da epiderme, seus vectores de expressao, processo de preparacao e composicoes farmaceuticas que os contem
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
DK1144006T3 (da) Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
NO962125L (no) Anti-idiotypiske antistoffer som induserer en immunrespons mot epidermal vekstfaktorreseptor
BR9702101A (pt) Hibridoma e anticorpo monoclonal
DK0656906T3 (da) Endothelcellemolekyle, der medierer lymfocytbinding i mennesket
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application